For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240408:nRSH5854Ja&default-theme=true
RNS Number : 5854J Byotrol PLC 08 April 2024
Byotrol Plc
("Byotrol" or the "Company")
Holdings in Company
Byotrol Plc (AIM: BYOT), the specialist infection prevention and control
company, announces that it has received notification that as of 5 April 2024,
Mr & Mrs D Newlands no longer have a notifiable interest in the Company's
issued share capital.
For further information contact:
Byotrol Plc
Dr Trevor Francis, Non- Executive Chairman +44 (0)1925 742 000
David Traynor, Interim Chief Executive Officer
Chris Sedwell, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Broker) +44 (0)20 7220 0500
Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Flagstaff Strategic and Investor Communications +44 (0)20 7129 1474
Tim Thompson/Andrea Seymour/Fergus Mellon byotrol@flagstaffcomms.com (mailto:byotrol@flagstaffcomms.com)
Notes to editors
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and
control company, operating globally in the animal and human healthare,
industrial, institutional and consumer sectors, providing low toxicity
products with a broad-based and targeted efficacy across all microbial
classes; bacteria, viruses (including coronavirus), fungi, moulds,
mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing
products, where they can significantly improve their performance, especially
in personal hygiene, domestic and industrial disinfection, odour control, food
production and food management.
Byotrol develops and commercialises technologies that create easier, safer and
cleaner lives for everyone.
For more information, go to byotrol.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END HOLQKPBDNBKBOQK